Familial Cancer (2017) 16:509–516 DOI 10.1007/s10689-017-9986-9
ORIGINAL ARTICLE
General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey Samuel G. Smith1,2 · Robbie Foy1 · Jennifer McGowan3 · Lindsay C. Kobayashi4 · John Burn5 · Karen Brown6 · Lucy Side7 · Jack Cuzick2
Published online: 22 April 2017 © The Author(s) 2017. This article is an open access publication
Abstract A dose non-inferiority study comparing 100 mg, 300 mg and 600 mg of aspirin for cancer prevention among Lynch Syndrome carriers is underway (Colorectal Adenoma/Carcinoma Prevention Programme trial 3, CaPP3). To guide implementation of the findings, we investigated general practitioner (GP) attitudes towards aspirin prescribing for Lynch Syndrome carriers. We surveyed 1007 UK GPs (9.6% response rate). Using a withinsubjects design, GPs read a statement on harms and benefits of aspirin and indicated their willingness to prescribe aspirin at three doses (100 mg, 300 mg, 600 mg). Approximately two-thirds (70.8%) of GPs had heard of Lynch Syndrome or its associated names, and among those 46.7% were aware of the cancer preventive effects of aspirin among carriers. Two-thirds (68.1%) of GPs reported feeling comfortable discussing harms and benefits of aspirin * Samuel G. Smith [email protected] 1
Leeds Institute of Health Sciences, University of Leeds, Floor 10, Worsley Building, Leeds LS2 9JT, UK
2
Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
3
Institute of Epidemiology and Healthcare, University College London, London, UK
4
Harvard T. H. Chan School of Public Health, Center for Population and Development Studies, Harvard University, Cambridge, MA, USA
5
Institute of Genetic Medicine, Newcastle University, Newcastle, UK
6
Department of Cancer Studies, University of Leicester, Leicester, UK
7
Institute for Women’s Health, University College London, London, UK
with a Lynch Syndrome patient. Willingness to prescribe was 91.3% at 100 mg, and declined to 81.8% at 300 mg and 62.3% at 600 mg (p
ORIGINAL ARTICLE
General practitioner attitudes towards prescribing aspirin to carriers of Lynch Syndrome: findings from a national survey Samuel G. Smith1,2 · Robbie Foy1 · Jennifer McGowan3 · Lindsay C. Kobayashi4 · John Burn5 · Karen Brown6 · Lucy Side7 · Jack Cuzick2
Published online: 22 April 2017 © The Author(s) 2017. This article is an open access publication
Abstract A dose non-inferiority study comparing 100 mg, 300 mg and 600 mg of aspirin for cancer prevention among Lynch Syndrome carriers is underway (Colorectal Adenoma/Carcinoma Prevention Programme trial 3, CaPP3). To guide implementation of the findings, we investigated general practitioner (GP) attitudes towards aspirin prescribing for Lynch Syndrome carriers. We surveyed 1007 UK GPs (9.6% response rate). Using a withinsubjects design, GPs read a statement on harms and benefits of aspirin and indicated their willingness to prescribe aspirin at three doses (100 mg, 300 mg, 600 mg). Approximately two-thirds (70.8%) of GPs had heard of Lynch Syndrome or its associated names, and among those 46.7% were aware of the cancer preventive effects of aspirin among carriers. Two-thirds (68.1%) of GPs reported feeling comfortable discussing harms and benefits of aspirin * Samuel G. Smith [email protected] 1
Leeds Institute of Health Sciences, University of Leeds, Floor 10, Worsley Building, Leeds LS2 9JT, UK
2
Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK
3
Institute of Epidemiology and Healthcare, University College London, London, UK
4
Harvard T. H. Chan School of Public Health, Center for Population and Development Studies, Harvard University, Cambridge, MA, USA
5
Institute of Genetic Medicine, Newcastle University, Newcastle, UK
6
Department of Cancer Studies, University of Leicester, Leicester, UK
7
Institute for Women’s Health, University College London, London, UK
with a Lynch Syndrome patient. Willingness to prescribe was 91.3% at 100 mg, and declined to 81.8% at 300 mg and 62.3% at 600 mg (p
